Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Purchased by Procyon Advisors LLC

Procyon Advisors LLC boosted its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 86.0% in the 1st quarter, according to its most recent Form 13F filing with the SEC. The fund owned 6,473 shares of the biopharmaceutical company's stock after purchasing an additional 2,992 shares during the period. Procyon Advisors LLC's holdings in Regeneron Pharmaceuticals were worth $4,106,000 as of its most recent filing with the SEC.

Several other large investors have also recently bought and sold shares of the stock. Rakuten Securities Inc. lifted its stake in Regeneron Pharmaceuticals by 62.5% in the 4th quarter. Rakuten Securities Inc. now owns 39 shares of the biopharmaceutical company's stock worth $28,000 after purchasing an additional 15 shares in the last quarter. TD Private Client Wealth LLC boosted its stake in shares of Regeneron Pharmaceuticals by 9.6% during the fourth quarter. TD Private Client Wealth LLC now owns 171 shares of the biopharmaceutical company's stock valued at $122,000 after purchasing an additional 15 shares in the last quarter. Manchester Capital Management LLC boosted its stake in shares of Regeneron Pharmaceuticals by 12.6% during the fourth quarter. Manchester Capital Management LLC now owns 161 shares of the biopharmaceutical company's stock valued at $115,000 after purchasing an additional 18 shares in the last quarter. Adirondack Trust Co. boosted its stake in shares of Regeneron Pharmaceuticals by 4.2% during the first quarter. Adirondack Trust Co. now owns 451 shares of the biopharmaceutical company's stock valued at $286,000 after purchasing an additional 18 shares in the last quarter. Finally, Financial Perspectives Inc boosted its stake in shares of Regeneron Pharmaceuticals by 10.9% during the fourth quarter. Financial Perspectives Inc now owns 193 shares of the biopharmaceutical company's stock valued at $137,000 after purchasing an additional 19 shares in the last quarter. 83.31% of the stock is owned by institutional investors and hedge funds.

Regeneron Pharmaceuticals Stock Up 2.1%

Shares of NASDAQ:REGN traded up $10.15 during trading hours on Friday, reaching $493.22. The stock had a trading volume of 1,497,861 shares, compared to its average volume of 860,334. Regeneron Pharmaceuticals, Inc. has a 1 year low of $476.49 and a 1 year high of $1,211.20. The firm's 50 day moving average is $569.75 and its 200-day moving average is $657.70. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.95 and a current ratio of 4.73. The stock has a market capitalization of $53.25 billion, a price-to-earnings ratio of 12.88, a P/E/G ratio of 2.34 and a beta of 0.31.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last announced its quarterly earnings data on Tuesday, April 29th. The biopharmaceutical company reported $8.22 EPS for the quarter, missing analysts' consensus estimates of $8.83 by ($0.61). Regeneron Pharmaceuticals had a net margin of 31.07% and a return on equity of 16.32%. The firm had revenue of $3.03 billion during the quarter, compared to analysts' expectations of $3.40 billion. During the same period in the prior year, the company posted $9.55 earnings per share. The company's revenue for the quarter was down 3.7% on a year-over-year basis. Research analysts predict that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Friday, June 6th. Stockholders of record on Tuesday, May 20th were issued a $0.88 dividend. This represents a $3.52 annualized dividend and a dividend yield of 0.71%. The ex-dividend date of this dividend was Tuesday, May 20th. Regeneron Pharmaceuticals's payout ratio is 8.96%.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently commented on REGN shares. Bank of America lowered their price objective on shares of Regeneron Pharmaceuticals from $575.00 to $547.00 and set an "underperform" rating for the company in a research note on Thursday, April 17th. BMO Capital Markets reduced their target price on shares of Regeneron Pharmaceuticals from $800.00 to $600.00 and set an "outperform" rating for the company in a report on Monday, June 2nd. Wall Street Zen cut shares of Regeneron Pharmaceuticals from a "buy" rating to a "hold" rating in a report on Thursday, May 1st. Guggenheim reissued a "buy" rating on shares of Regeneron Pharmaceuticals in a research note on Friday, May 30th. Finally, Morgan Stanley cut their target price on shares of Regeneron Pharmaceuticals from $958.00 to $755.00 and set an "overweight" rating for the company in a research note on Monday, June 2nd. One analyst has rated the stock with a sell rating, six have given a hold rating, seventeen have assigned a buy rating and three have assigned a strong buy rating to the stock. Based on data from MarketBeat, Regeneron Pharmaceuticals has a consensus rating of "Moderate Buy" and an average target price of $844.48.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.